Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Best Growth Stocks to Buy for December 22nd

Published 12/22/2021, 12:26 AM
Updated 07/09/2023, 06:31 AM

Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, December 22nd:

ArcBest (NASDAQ:ARCB) Corporation ARCB: This provider of freight transportation and integrated logistics services carries a Zacks Rank #1 (Strong Buy), has witnessed the Zacks Consensus Estimate for its current year earnings increasing 9.2% over the last 60 days.

ArcBest has a PEG ratio of 0.30 compared with 0.84 for the industry. The company possesses a Growth Score of A.

The Chemours Company (NYSE:CC) CC: This provider of performance chemicals carries a Zacks Rank #1, has witnessed the Zacks Consensus Estimate for its current year earnings increasing 10% over the last 60 days.

Chemours has a PEG ratio of 0.23, compared with 0.65 for the industry. The company possesses a Growth Score of A.

Greif (NYSE:GEF), Inc. GEF: This provider of industrial packaging products and services carries a Zacks Rank #1, has witnessed the Zacks Consensus Estimate for its current year earnings increasing 5.6% over the last 60 days.

Greif, Inc. Price and Consensus

Greif, Inc. price-consensus-chart | Greif, Inc. Quote

Greif has a PEG ratio of 0.93, compared with 1.65 for the industry. The company possesses a Growth Score of B.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Greif, Inc. PEG Ratio (TTM)

Greif, Inc. peg-ratio-ttm | Greif, Inc. Quote

See the full list of top ranked stocks here.

Learn more about the Growth score and how it is calculated here.


Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.

See these 7 breakthrough stocks now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Greif, Inc. (GEF): Free Stock Analysis Report

ArcBest Corporation (ARCB): Free Stock Analysis Report

The Chemours Company (CC): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.